(Tromsø 18. May 2021) Volker Wedershoven, member of the Board of Directors, has
today sold 20.000 shares in ArcticZymes Technologies ASA at NOK 85,12 per share

Following this transactions holds Mr. Wedershoven 60.000 shares and 100.000
options in the company.
This notification is prepared in accordance with the EU Market Abuse Regulation
art. 19 and the Securities Trading Act section 5-12.


About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company focused on the
development, manufacturing and commercialization of novel recombinant enzymes
for use in molecular research, In Vitro Diagnostics (IVD) and therapeutics.

Listed on the Oslo Stock Exchange since 2005 originally under the [Biotec]
ticker, as Biotec Pharmacon. The company rebranded as ArcticZymes Technologies
in 2020 under the [AZT] ticker. Its headquarters are based in Tromsø, Norway, at
the SIVA Innovation Centre.

ArcticZymes Technologies' IP and capabilities are protected via a large
portfolio of patents.

For more information, please visit the website: www.arcticzymes.com.